Onxeo SA
PAR:ALONX
Operating Margin
Onxeo SA
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
FR |
O
|
Onxeo SA
PAR:ALONX
|
30.2m EUR |
-1 186%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
336.1B USD |
30%
|
|
US |
![]() |
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 834%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
164.8B USD |
25%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
144.7B USD |
38%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.7B USD |
38%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
131.1B AUD |
26%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.9B USD |
29%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Onxeo SA
Glance View
Onxeo SA is a is a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2005-07-12. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Onxeo SA's most recent financial statements, the company has Operating Margin of -1 186.1%.